These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21712478)

  • 21. Targeting CD30 in anaplastic large cell lymphoma.
    Vadakara J; Pro B
    Curr Hematol Malig Rep; 2012 Dec; 7(4):285-91. PubMed ID: 23065407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
    Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
    Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The emerging role of CD30 and p53 as novel targets for therapy in anaplastic large cell lymphoma.
    Rassidakis GZ; Drakos E
    Front Biosci (Elite Ed); 2016 Jan; 8(1):61-71. PubMed ID: 26709646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.
    Wang R; Li L; Duan A; Li Y; Liu X; Miao Q; Gong J; Zhen Y
    Cancer Lett; 2019 Apr; 448():84-93. PubMed ID: 30742941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.
    Falini B; Bigerna B; Fizzotti M; Pulford K; Pileri SA; Delsol G; Carbone A; Paulli M; Magrini U; Menestrina F; Giardini R; Pilotti S; Mezzelani A; Ugolini B; Billi M; Pucciarini A; Pacini R; Pelicci PG; Flenghi L
    Am J Pathol; 1998 Sep; 153(3):875-86. PubMed ID: 9736036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders.
    Su LD; Schnitzer B; Ross CW; Vasef M; Mori S; Shiota M; Mason DY; Pulford K; Headington JT; Singleton TP
    J Cutan Pathol; 1997 Nov; 24(10):597-603. PubMed ID: 9449486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
    Cools J; Wlodarska I; Somers R; Mentens N; Pedeutour F; Maes B; De Wolf-Peeters C; Pauwels P; Hagemeijer A; Marynen P
    Genes Chromosomes Cancer; 2002 Aug; 34(4):354-62. PubMed ID: 12112524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.
    K Singh V; Werner S; Hackstein H; Lennerz V; Reiter A; Wölfel T; Damm-Welk C; Woessmann W
    Clin Exp Immunol; 2016 Oct; 186(1):96-105. PubMed ID: 27414060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY; Johnston PB; Burke KA; Zhao Y
    Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.
    Wang X; Wu J; Zhang M
    Hematology; 2019 Dec; 24(1):440-445. PubMed ID: 31072226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma.
    Kutok JL; Aster JC
    J Clin Oncol; 2002 Sep; 20(17):3691-702. PubMed ID: 12202671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).
    Colleoni GW; Bridge JA; Garicochea B; Liu J; Filippa DA; Ladanyi M
    Am J Pathol; 2000 Mar; 156(3):781-9. PubMed ID: 10702393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.
    Ambrogio C; Voena C; Manazza AD; Martinengo C; Costa C; Kirchhausen T; Hirsch E; Inghirami G; Chiarle R
    Cancer Res; 2008 Nov; 68(21):8899-907. PubMed ID: 18974134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
    Fernandez-Vidal A; Mazars A; Gautier EF; Prévost G; Payrastre B; Manenti S
    Cell Cycle; 2009 May; 8(9):1373-9. PubMed ID: 19305144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.
    Atsaves V; Lekakis L; Drakos E; Leventaki V; Ghaderi M; Baltatzis GE; Chioureas D; Jones D; Feretzaki M; Liakou C; Panayiotidis P; Gorgoulis V; Patsouris E; Medeiros LJ; Claret FX; Rassidakis GZ
    Br J Haematol; 2014 Nov; 167(4):514-23. PubMed ID: 25145835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK.
    Larose H; Burke GAA; Lowe EJ; Turner SD
    Br J Haematol; 2019 Jun; 185(6):1043-1054. PubMed ID: 30681723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center.
    Park SJ; Kim S; Lee DH; Jeong YP; Bae Y; Han EM; Huh J; Suh C
    Yonsei Med J; 2008 Aug; 49(4):601-9. PubMed ID: 18729302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.
    Redaelli S; Ceccon M; Antolini L; Rigolio R; Pirola A; Peronaci M; Gambacorti-Passerini C; Mologni L
    Oncotarget; 2016 Nov; 7(45):72886-72897. PubMed ID: 27662658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.